VG HCQ Advances in Early-Stage Trial

VG Life Sciences has updated its Phase I study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors. The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar), which was co-developed by Bayer AG and Onyx Pharmaceuticals. VG Life Sciences, Inc. holds the use patent for this combination treatment.

The study is reporting two clinical responses in cohort 3: disease stabilization in a patient with metastatic ovarian cancer for four months, and disease stabilization going into its fifth month in a patient with triple negative breast cancer. Further test information and data will be forthcoming.

The fourth and final cohort will begin in January, which will increase the HCQ dosage from cohort 3. For procedural reasons, the start of the final cohort was delayed.